On the other hand, the observation that high levels of AurkA and TPX2 are associated with taxane-based radiosensitisation [98], a strategy currently used in clinical protocols for a large spectrum of tumours, suggests that their involvement in therapeutic responses may depend on tumour or treatment specificity, highlighting the need for further investigation. This evidence concerns the gene AURKA and neoplasm.